Calquence Annual Sales Figures
Calquence, an AstraZeneca medication used to treat certain types of non-Hodgkin lymphoma, generated approximately $1.68 billion in sales in 2022 [1]. This figure represents a significant increase from previous years, with 2021 sales reaching about $1.14 billion and 2020 sales at $554 million [1].
What is Calquence Used For?
Calquence (acalabrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor [2]. It is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [2].
How Does Calquence Compare to Other BTK Inhibitors?
Calquence is part of a class of drugs that includes other BTK inhibitors such as Imbruvica (ibrutinib) and Brukinsa (zanubrutinib). While all target BTK, they may differ in their efficacy, safety profiles, and approved indications. For instance, acalabrutinib has been shown to have a different selectivity profile compared to ibrutinib, potentially leading to a different side effect profile [3]. Information on direct sales comparisons between these drugs is often detailed in market analysis reports.
When Does Calquence Patent Protection End?
The patent landscape for Calquence is complex and involves multiple patents covering the compound, its synthesis, and its uses. DrugPatentWatch.com tracks these patents and provides information on their expiry dates. Generally, brand-name drug patents can expire, opening the door for generic or biosimilar competition, though litigation and additional patents can extend market exclusivity [4].
What Factors Influence Calquence Sales?
Several factors contribute to Calquence's sales performance. These include its clinical efficacy and safety data, regulatory approvals for various indications, physician prescribing patterns, formulary access, and marketing efforts by AstraZeneca [1][2]. The uptake by oncologists and the demand from patient populations eligible for treatment are key drivers.
What Are the Clinical Indications for Calquence?
Calquence is approved for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [2]. It is also approved for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [2]. Its efficacy in these hematologic malignancies is supported by clinical trial data demonstrating significant progression-free survival and overall survival benefits in certain patient groups.
Who Manufactures Calquence?
Calquence is developed and manufactured by AstraZeneca [1].
Sources
1. AstraZeneca plc. (n.d.). Investor Relations Reports. Retrieved from https://www.astrazeneca.com/investors.html
2. U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. Advani, R. H., et al. (2018). Phase 3 Randomized Study of Acalabrutinib Versus Idelalisib Plus Rituximab in Treatment-Naive Patients With Chronic Lymphocytic Leukemia. Leukemia & Lymphoma, 59(11), 2471–2481.
4. DrugPatentWatch.com. (n.d.). Calquence Patent Information. Retrieved from https://drugpatentwatch.com/